文献速递神经肿瘤

患者来源骨髓间充质干细胞作为溶瘤病毒载体治疗胶质母细胞瘤的特征分析

Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma.
PubMed 文献 · J Neurosurg · 2021-08-27

该前瞻性临床试验纳入5例曾接受放疗和化疗的复发性恶性胶质瘤患者,从其髂嵴获取骨髓并培养出骨髓间充质干细胞(BM-hMSCs)。患者来源的BM-hMSCs形态、表面标志物及分化能力与健康供者来源者相似,且能有效递送溶瘤腺病毒Delta-24-RGD,在体外根除人胶质瘤细胞,在小鼠体内延长荷瘤小鼠生存期。

要点

  • 曾接受骨髓毒性化疗的胶质瘤患者仍可成功获取BM-hMSCs。
  • 患者来源BM-hMSCs保持间充质干细胞特征并可分化为成骨、成脂和成软骨细胞。
  • 负载Delta-24-RGD的患者来源BM-hMSCs可有效递送溶瘤病毒并延长小鼠生存。

核心结论

  • BM-hMSCs可从既往接受骨髓毒性化疗的患者中获取,且患者来源BM-hMSCs是溶瘤病毒的有效载体。

研究设计与样本

  • 前瞻性临床试验,连续纳入5例接受过放疗和化疗的复发性恶性胶质瘤患者。
  • 从髂嵴获取骨髓穿刺液并培养获得BM-hMSCs,进行形态、流式细胞术和分化实验。
  • 在小鼠颅内胶质瘤异种移植模型中评估经颈动脉递送后的归巢能力。
  • 体外评估负载Delta-24-RGD的患者来源BM-hMSCs(PD-BM-MSC-D24)对胶质瘤细胞的杀伤效果。
  • 体内研究评估血管内注射PD-BM-MSC-D24对U87MG胶质瘤小鼠生存的影响。

主要发现

  • 患者来源BM-hMSCs形态与健康供者来源BM-hMSCs相似。
  • 流式细胞术显示全部5株细胞系表达经典间充质干细胞表面标志物。
  • 这些培养物可被诱导分化为成骨细胞、脂肪细胞和软骨细胞。
  • 经颈动脉递送后,患者来源BM-hMSCs归巢至小鼠颅内胶质瘤异种移植物的效果与健康供者来源BM-hMSCs相当。
  • 负载Delta-24-RGD的患者来源BM-hMSCs在体外有效根除人胶质瘤细胞。

临床怎么用

  • 对于既往接受骨髓毒性化疗的复发性恶性胶质瘤患者,可考虑获取自体BM-hMSCs作为溶瘤病毒递送载体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Delta-24-RGD is an oncolytic adenovirus that is capable of replicating in and killing human glioma cells. Although intratumoral delivery of Delta-24-RGD can be effective, systemic delivery would improve its clinical application. Bone marrow-derived human mesenchymal stem cells (BM-hMSCs) obtained from healthy donors have been investigated as virus carriers. However, it is unclear whether BM-hMSCs can be derived from glioma patients previously treated with marrow-toxic chemotherapy or whether such BM-hMSCs can deliver oncolytic viruses effectively. Herein, the authors undertook a prospective clinical trial to determine the feasibility of obtaining BM-hMSCs from patients with recurrent malignant glioma who were previously exposed to marrow-toxic chemotherapy. METHODS: The authors enrolled 5 consecutive patients who had been treated with radiation therapy and chemotherapy. BM aspirates were obtained from the iliac crest and were cultured to obtain BM-hMSCs. RESULTS: The patient-derived BM-hMSCs (PD-BM-hMSCs) had a morphology similar to that of healthy donor-derived BM-hMSCs (HD-BM-hMSCs). Flow cytometry revealed that all 5 cell lines expressed canonical MSC surface markers. Importantly, these cultures could be made to differentiate into osteocytes, adipocytes, and chondrocytes. In all cases, the PD-BM-hMSCs homed to intracranial glioma xenografts in mice after intracarotid delivery as effectively as HD-BM-hMSCs. The PD-BM-hMSCs loaded with Delta-24-RGD (PD-BM-MSC-D24) effectively eradicated human gliomas in vitro. In in vivo studies, intravascular administration of PD-BM-MSC-D24 increased the survival of mice harboring U87MG gliomas. CONCLUSIONS: The authors conclude that BM-hMSCs can be acquired from patients previously treated with marrow-toxic chemotherapy and that these PD-BM-hMSCs are effective carriers for oncolytic viruses.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Shimizu Y, Gumin J, Gao F, et al. Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma. J Neurosurg. 2021. PMID: 34450587. doi:10.3171/2021.3.JNS203045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。